Article citationsMore>>
Fattovich, G., Giustina, G., Sanchez-Tapias, J., Quero, C., Mas, A., Olivotto, P.G., Solinas, A., Almasio, P., Hadziyannis, S., Degos, F., de Moura, M.C., Krogsgaard, K., Pantalena, M., Realdi, G., Corrocher, R. and Schalm, S.W. (1998) Delayed Clearance of Serum HBsAg in Compensated Cirrhosis B: Relation to Interferon Alpha Therapy and Disease Prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). American Journal of Gastroenterology, 93, 896-900.
http://dx.doi.org/10.1111/j.1572-0241.1998.00272.x
has been cited by the following article:
-
TITLE:
The Role of Circulating MicroRNAs as Markers of Disease Progression in Hepatitis C Virus Infected Egyptian Patients
AUTHORS:
Reem Abdel Hamid Harfoush, Marwa Ahmed Meheissen, Reham Abel Haleem Abo Elwafa, Doaa Ahmed Elwazzan
KEYWORDS:
MicroRNA, Hepatocellular Carcinoma, Hepatitis C Virus
JOURNAL NAME:
Advances in Microbiology,
Vol.6 No.4,
April
20,
2016
ABSTRACT: Background: The discovery of miRNAs circulating in the peripheral blood has opened new directions
of research to identify new non-invasive markers for diagnosis of diseases. Aim: The aim of the study
was to evaluate the expression levels of circulating plasma miRNAs (miRNA-21 & miRNA-122) in
Egyptian patients with chronic uncomplicated and complicated HCV. Patients & Methods: This study
was conducted on 60 Chronic HCV infected patients. Patients were divided into three groups (20 patients
each): uncomplicated HCV, cirrhosis, and hepatocellular carcinoma (HCC). All patients were
subjected to laboratory investigations including complete blood picture, liver function tests. Expression
levels of miRNA-21 and -122 in plasma using RT-PCR were determined. Results: MiRNA-21 showed significant fold increase in chronic uncomplicated HCV while significant fold decrease
in cirrhotic and HCC groups (P = 0.036). On the other hand, miRNA-122 showed significant fold elevation
in both chronic uncomplicated and cirrhotic groups and significant fold decrease in HCC
group (P = 0.005). ROC curve analysis for miRNA-122 yielded 68.4% sensitivity and 100% specificity
for the differentiation of HCC patients from non-HCC at a cutoff 0.184. Neither miRNA-21 nor miRNA-122 was a successful predictor for HCC diagnosis. Conclusion: MiRNA-122 can be used as novel
non-invasive biomarker for monitoring HCV related disease progression.
Related Articles:
-
Ruben Cabrera, Arsenio J. Areces, Jhoana Díaz-Larrea, Laura Nuñez García, J. Ricardo Cruz-Aviña
-
Nadège Goumkwa Mafopa, Raoul Emeric Guetiya Wadoum, Marta Giovanetti, Antonella Minutolo, Béatrice Dambaya, Claude Kwe Yinda, Gianluca Russo, Georges Teto, Georgia Ambada, Patrick Turay, Judith Torimiro, Alexis Ndjolo, Jules Roger Kuate, Vittorio Colizzi, Carla Montesano
-
Karolj Skala, Davor Davidović, Tomislav Lipić, Ivan Sović
-
Charu Shrestha, Ashita Uppoor, Dilip Nayak
-
Mohammad Ilyas, Reyaz Ahmad, Shadab Ilyas